



SUPPLEMENTARY FIGURES




Supplementary Figure 1. ROC curves illustration of the identified immune signature risk scores of the 3 cohorts included in this study.

A Wilcoxon test $P = 0.886$



B Wilcoxon test $P = 0.957$



Supplementary Figure 2. The distribution of (A) TMB and (B) neoantigen burden in low-risk versus high-risk subgroups in the melanoma immunotherapy cohort.